Bain Capital Life Sciences Investors, LLC Adagio Therapeutics, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $370 Million
- Q4 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,799,595 shares of ADGI stock, worth $5.96 Million. This represents 1.61% of its overall portfolio holdings.
Number of Shares
1,799,595
Previous 1,799,595
-0.0%
Holding current value
$5.96 Million
Previous $5.96 Million
-0.0%
% of portfolio
1.61%
Previous 1.07%
Shares
3 transactions
Others Institutions Holding ADGI
# of Institutions
76Shares Held
70.5MCall Options Held
3.6KPut Options Held
2.1K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.75% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million30.95% of portfolio
-
Deep Track Capital, LP Greenwich, CT10.7MShares$35.4 Million1.56% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million24.88% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...